Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | DHFR | P00374 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8871609 | 0.92 | ALDH1A1 (0.56) | CYP1A2CYP2C9CYP2C19ALDH1A1DHFR | |
| SCHEMBL13427166 | 0.84 | CYP1A2 (0.57) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL29213722 | 0.84 | TDP1 (0.64) | CYP1A2CYP2C19ALDH1A1TDP1USP2 | |
| SCHEMBL7335908 | 0.84 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19ALDH1A1DHFR | |
| SCHEMBL27921658 | 0.83 | LMNA (0.59) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL3267158 | 0.83 | TDP1 (0.51) | ALDH1A1DHFRTDP1L3MBTL1CYP4F2 | |
| SCHEMBL3268399 | 0.83 | JAK2 (0.53) | CYP1A2CYP2C9CYP2C19DHFRTDP1 | |
| SCHEMBL9031198 | 0.83 | MEN1 (0.43) | CYP1A2DHFRTDP1L3MBTL1MEN1 | |
| SCHEMBL9034108 | 0.83 | MEN1 (0.46) | CYP1A2ALDH1A1DHFRTDP1L3MBTL1 | |
| SCHEMBL20150488 | 0.83 | ALDH1A1 (0.59) | CYP1A2CYP2C9CYP2C19ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933067-B2 | Pyrido and pyrimidopyrimidine derivatives as anti-profilerative agents | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8772272-B2 | Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents | JANSSEN PHARMACEUTICA NV (BG) | 2014-07-08 | — | — | US | disclosed |
| US-20130231353-A1 | PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROFILERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-05 | — | — | US | disclosed |
| US-7799772-B2 | tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-21 | — | — | US | disclosed |
| US-20100173913-A1 | PYRIDO-AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-08 | — | — | US | disclosed |
| EP-1697384-B1 | PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-02 | — | — | EP | disclosed |
| US-20070078132-A1 | tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer | JANSSEN-CILAG (FR) | 2007-04-05 | — | — | US | disclosed |
| EP-1697384-A1 | PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058913-A1 | PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI- PROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-30 | — | — | WO | disclosed |
| US-6211242-B1 | CARDIOVASCULAR DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0291247-B1 | NOVEL CINNAMOYLAMIDE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0291245-B1 | BENZOYLAMINOPHENOXYBUTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-07-22 | — | — | EP | disclosed |
| US-4980372-A | INHIBITORS OF 5-ALPHA-REDUCTASE; TREATING AND PREVENTING ALOPECIA, ACNES OR PROSTATIC HYPERTROPHY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1990-12-25 | — | — | US | disclosed |
| US-4935240-A | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| US-4863963-A | 5-A-REDUCTASE INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0294937-A2 | Novel cinnamoylamide derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-14 | — | — | EP | disclosed |
| EP-0294035-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-07 | — | — | EP | disclosed |
| EP-0291245-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-11-17 | — | — | EP | disclosed |
| EP-0291247-A2 | Novel cinnamoylamide derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078132-A1 | tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer | NR1H3, NR1H2, ERBB2 | CYP1A2 510/4885CYP2C9 999/4885CYP2C19 351/4885 |
| US-20130231353-A1 | PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROFILERATIVE AGENTS | NR4A1, CYP2J2, NR3C2 | CYP1A2 37/4885CYP2C9 237/4885CYP2C19 45/4885 |
| US-20100173913-A1 | PYRIDO-AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS | CYP2J2, NR4A1, ALOX15 | CYP1A2 62/4885CYP2C9 304/4885CYP2C19 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.